Table 2.
Population pharmacokinetic parameter estimates
| Parameter (unit) | Estimate | RSE (%) |
|---|---|---|
| V1 (L) | 2.9 | 8 |
| CL (L/day) | 0.23 | 10 |
| MTV on V1 | 0.00012 | 36 |
| BW on V1 | 0.49 | 45 |
| V2 (L) | 5.0 | 9 |
| Q (L/day) | 1.8 | 28 |
| L0 (nmol.cm−3) | 3.1 | 18 |
| Kdeg (cm3.nmol−1.day−1) | 0.000079 | 17 |
| ωV1 | 0.19 | 28 |
| ωCL | 0.42 | 19 |
| ωL0 | 0.35 | 34 |
| σprop | 0.26 | 8 |
RSE, relative standard error; V1, V2: central and peripheral volumes of distribution; CL, Q: systemic and intercompartment clearances; MTV: metabolic tumour volume; BW: body weight, L0, initial latent target amount available for rituximab by unit of MTV; Kdeg, second‐order target‐mediated elimination rate; ωV1, ωCL, ωL0: interindividual standard deviations of V1, CL and L0, respectively; σprop: residual proportional error.